Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 11:20 a.m. PT in Las Vegas. CEO Kevin Gorman and CFO Matt Abernethy will represent the company. The presentation will be available via live webcast on the company's website, with a replay accessible after one hour post-event for about a month. Neurocrine focuses on developing treatments for neurological and neuropsychiatric disorders, with a range of FDA-approved therapies and ongoing clinical programs.

News Market Reaction – NBIX

-0.34%

-0.34% Session move

In the trading session that priced this news, NBIX declined 0.34%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 3, 2022  /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2022 Healthcare Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday, May 10, 2022 in Las Vegas. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-bank-of-america-securities-2022-healthcare-conference-301538807.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

What is the date and time of Neurocrine's presentation at the Bank of America Conference?

Neurocrine's presentation is scheduled for May 10, 2022, at 11:20 a.m. Pacific Time.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman and CFO Matt Abernethy will present for Neurocrine Biosciences.

Where can I watch the Neurocrine presentation live?

The live presentation can be accessed on Neurocrine's website under the Investors section.

How long will the presentation replay be available on Neurocrine's website?

The replay of the presentation will be available approximately one hour after it concludes and will be archived for about one month.

What areas does Neurocrine Biosciences focus on?

Neurocrine is focused on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.